Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biomedicines|May 27, 2026
Functionalized Lipid Nanoparticles for Targeted RNA Delivery in Immune and Inflammatory DiseasesYeongji Jang, Hyun Kyu Song, Man Kyu Shim, et al.
Plastic and Reconstructive Surgery|June 15, 2026
Therapeutic Potential of Bovine Colostrum-Derived Exosomes for Ischemia-Reperfusion Injury in Skin Flaps: A Rat Model StudyYoung Chul Kim, Yeongji Jang, Youngsam Kim, et al.
Pharmaceutics|June 24, 2022
The Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer CellsYelee Kim, Hyosuk Kim, Eun Hye Kim, et al.
Frontiers in Cell and Developmental Biology|April 1, 2022
Potential of Colostrum-Derived Exosomes for Promoting Hair Regeneration Through the Transition From Telogen to Anagen PhaseHyosuk Kim, Yeongji Jang, Eun Hye Kim, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 23, 2024
Design of PD-L1-Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer TherapyYelee Kim, Jiwoong Choi, Eun Hye Kim, et al.
Biomaterials Research|November 29, 2023
Post-insertion technique to introduce targeting moieties in milk exosomes for targeted drug deliveryHochung Jang, Hyosuk Kim, Eun Hye Kim, et al.
Advanced Healthcare Materials|December 5, 2021
Harnessing the Natural Healing Power of Colostrum: Bovine Milk-Derived Extracellular Vesicles from Colostrum Facilitating the Transition from Inflammation to Tissue Regeneration for Accelerating Cutaneous Wound HealingHyosuk Kim, Da Eun Kim, Geonhee Han, et al.
Biomaterials Science|March 22, 2022
Bovine colostrum derived-exosomes prevent dextran sulfate sodium-induced intestinal colitis via suppression of inflammation and oxidative stressGeonhee Han, Haeun Cho, Hyosuk Kim, et al.
Small (Weinheim an Der Bergstrasse, Germany)|July 22, 2025
Targeted Delivery of miR-34a via Anti-CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast CancerYoungri Ryu, Eun Hye Kim, Hochung Jang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 9, 2022
PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMsEun Hye Kim, Jongwon Lee, Gijung Kwak, et al.
Pageof 2